This episode of Digital Pathology Today™ our guest is John Wirthlin, CEO, Lumea

Too many systems or components in a pathology workflow adds complexity and cost. How can we create an elegant end to end solution to enhance workflows, while decreasing both complexity and costs?

We discuss the end-to-end solution in digital pathology. One of the promises of digital pathology is making the pathologist’s workflow more streamlined and more efficient. But can we bring the Laboratory Information System (LIS) into the clinic and improve the workflow flow for our clinician colleagues as well. How can we improve the tissue handling or preanalytic phase of testing? It's often easy to forget who the customer is. By utilizing enhanced workflows, can we improve satisfaction for the clinician, who is ultimately treating the patient?

John Wirthlin

CEO

Lumea

John B. Wirthlin has dedicated his career to commercializing innovative healthcare technologies that improve patient care. Mr. Wirthlin is the CEO of Lumea, a technology company that is disrupting the science and business of pathology through the commercialization of its next generation digital pathology platform. Better technology, coupled with a better business model, is empowering Lumea’s customers to thrive and grow in the diagnostic market. Prior to Lumea, Mr. Wirthlin founded AlloCure and raised over $50MM to develop new therapeutics for kidney disease. Over the course of his career, Mr. Wirthlin has led technology development in drug discovery, GMP manufacturing, artificial intelligence histology and pathology.